Parnassus Investments, an investment management firm, recently released its “Parnassus Value Equity Fund” third-quarter 2025 investor letter. The fund focuses on owning a concentrated portfolio of U.S. large-cap stocks and reported a net return of 7.46% for the third quarter, outperforming its benchmark, the Russell 1000 Value Index, which returned 5.33% for the same period.
During the quarter, the fund made strategic moves by reducing its weight in the IT sector to increase holdings in the Health Care sector. The letter also listed the fund’s top 5 holdings, giving insight into the firm’s main investment positions heading into 2025.
One stock highlighted in the investor letter was Novo Nordisk A/S (NYSE:NVO), a pharmaceutical company engaged in research, development, manufacturing, and distribution of pharmaceutical products. Despite a one-month return of -0.36%, Novo Nordisk A/S (NYSE:NVO) saw its shares lose 53.82% of their value over the last 52 weeks. On December 17, 2025, the stock closed at $47.77 per share, with a market capitalization of $212.265 billion.
In the third-quarter 2025 investor letter, Parnassus Value Equity Fund expressed confidence in Novo Nordisk A/S (NYSE:NVO) despite the recent decline in share price. The company issued a profit warning due to increased competition in the obesity drug market. However, the firm maintained its conviction in Novo Nordisk A/S (NYSE:NVO) citing the company’s long-term pipeline and potential catalysts in its oral GLP-1 launch.
While Novo Nordisk A/S (NYSE:NVO) is not among the 30 Most Popular Stocks Among Hedge Funds, 50 hedge fund portfolios held the stock at the end of the third quarter, up from 45 in the previous quarter. The firm believes that certain AI stocks offer greater upside potential and carry less downside risk compared to Novo Nordisk A/S (NYSE:NVO).
For more insights on Novo Nordisk A/S (NYSE:NVO), GreensKeeper Asset Management’s views on the company, and additional hedge fund investor letters from Q3 2025, readers can refer to the mentioned articles.
In conclusion, Parnassus Investments’ strategic moves and confidence in Novo Nordisk A/S (NYSE:NVO) showcase the firm’s approach to value investing in the current market landscape. Investors looking for opportunities in the pharmaceutical sector may find the insights from the investor letter valuable.
Disclosure: None. This article was originally published on Insider Monkey.
